BWAY Brainsway Ltd.

BUSINESS SUMMARY

Brainsway is an Israeli medical-device company focused on Deep Transcranial Magnetic Stimulation (Deep TMS) for psychiatric and neurological conditions. The flagship system uses an FDA-cleared H-Coil helmet to deliver magnetic pulses that stimulate deeper brain regions than the figure-of-eight coils used in conventional TMS systems.

The platform's FDA clearances span major depressive disorder (the largest indication and primary commercial volume), obsessive-compulsive disorder (where Brainsway has unique clinical positioning), smoking cessation, and several adjacent indications under continued clinical development.

Revenue is system placement (sales or lease arrangements) at psychiatric clinics, hospital-based psychiatry departments, and TMS-specialty providers, plus recurring per-treatment-session revenue from the consumables and service stream. Once a clinic commits to Brainsway, switching costs are real because of equipment investment and clinician-credentialing.

MARKET OPPORTUNITY

Major depression remains an enormous structural problem in mental healthcare:

• ~16 million US adults experience major depression annually
• 30-40% are treatment-resistant to first-line SSRIs and other antidepressants
• TMS has emerged as a credible non-medication option for this treatment-resistant population

Within TMS, Brainsway competes against Neuronetics' NeuroStar (the larger competitor and category leader by installed-base) plus several smaller TMS-system providers. Brainsway's H-coil-Deep TMS positioning emphasizes deeper brain-region stimulation, which carries some clinical-evidence support for specific conditions (notably OCD where the clearance is unique) but a less-decisive advantage in major depression.

Revenue growth has been moderate but inconsistent — quarter-by-quarter depends on system-placement timing combined with treatment-utilization at existing sites.

REVENUE QUALITY

• Gross margin — moderate-to-high; reflects medical-device and consumables economics
• Operating margin — TTM positive, improving with operational scale
• Revenue ~$50M+ TTM
• P/S ~10 — premium reflecting medical-device-thematic-investor demand

What investors should track: system-installation count plus treatment-volume per system. Aggregate revenue blends new-system-placement (lumpy capital revenue) with recurring-treatment-session revenue.

COMPETITIVE ADVANTAGE

The defensible asset is the Deep TMS H-coil patent estate plus the OCD-specific FDA clearance:

• H-coil patent protection for the deep-brain-stimulation approach
• Unique OCD clearance that NeuroStar doesn't have
• Multi-year clinic-relationship base with switching costs once equipment is installed

The vulnerability: in major depression — the largest commercial indication — clinical evidence supports both Deep TMS and conventional TMS, and NeuroStar has substantially larger installed base, sales-team scale, and brand recognition among prescribing psychiatrists.

GROWTH THESIS

Three structural drivers support multi-year growth:

1. Continued TMS adoption in psychiatry as evidence-base grows and reimbursement environment matures
2. OCD indication-specific market expansion where Deep TMS has unique positioning
3. International market scaling beyond the established US installed base

The wildcard is whether Deep TMS gains meaningful share against NeuroStar in the dominant major-depression indication or remains a specialty-positioning option for specific use cases.

KEY RISKS

1. Competitive pressure from NeuroStar in the dominant depression market. NeuroStar's larger scale and sales-team-presence create structural disadvantage for Deep TMS market-share growth in this indication.

2. Reimbursement-rate compression. TMS treatment reimbursement has been stable but not without pressure; meaningful rate-cuts would compress per-treatment economics.

3. Israeli-domiciled-company governance and currency dynamics. Operating from Israel adds currency-and-political-risk overhead that pure-US-operating peers don't carry.

VERDICT

Brainsway is a focused TMS-medical-device position with unique OCD-specific positioning combined with continued participation in the larger depression-treatment market. The 71.6/100 score captures the operational quality.

For investors who want non-medication-mental-health-treatment exposure with technology-and-IP differentiation, BWAY is one of few small-cap pure-plays. For investors needing scale or wanting the dominant TMS-platform exposure, Neuronetics (NeuroStar) is the alternative despite different growth profile.